Tolerability and Pharmacokinetics/-Dynamics of Single Rising Doses BIBT 986 BS in Healthy Male Subjects

Inclusion Criteria: * Healthy male subjects as determined by results of screening * Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation * Age \>= 18 and \<= 55 years * BMI \>= 18.5 and \<= 29.9 kg/m2 Exclusion Criteria: * Any finding of the medical examination (including blood pressure, pulse rate, and electrocardiogram) deviating from normal and of clinical relevance * Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic or hormonal disorders * Surgery of gastrointestinal tract (except appendectomy) * Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders * Relevant history of orthostatic hypotension, fainting spells or blackouts * Any bleeding disorder including prolonged or habitual bleeding * History of other hematologic disease, cerebral bleeding (e.g. after a car accident), commotio cerebri * Chronic or relevant acute infections * History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator * Seasonal rhinitis * Thrombocytes \< 150000/μl * Intake of drugs with a long half-life (\> 24 hours) (\< 1 month prior to administration or during the trial) * Use of any drugs, which might influence the results of the trial (\< 10 days prior to administration or during the trial) * Participation in another trial with an investigational drug (\< 2 months prior to administration or during trial) * Smoker (\> 10 cigarettes or \>3 cigars or \>3 pipes/day) * Alcohol abuse (\> 60 g/day) * Drug abuse * Use of methylxanthine-containing drinks or foods (coffee, tea, cola, energy drinks, chocolate, etc.), grapefruit or grapefruit juice, alcohol, green tea, or tobacco \< 5 days prior to administration of study drug or during trial * Blood donation or loss \> 400 ml, \< 1 month prior to administration or during the trial * Excessive physical activities \< 5 days prior to administration of study drug or during trial * Clinically relevant laboratory abnormalities * Any ECG value outside of the reference range of clinical relevance including, but not limited to QRS interval \> 110 ms or QTcB \> 450 ms * Inability to comply with dietary regimen of study centre * Inability to comply with investigator's instructions